Should we continue to use renin-angiotensin-aldosterone system blockers in patients with COVID-19?

被引：1
作者：
Copur, Sidar [1 ]
Kanbay, Asiye [2 ]
Kanbay, Mehmet [3 ]
机构：
[1] Koc Univ, Sch Med, Dept Med, Istanbul, Turkey
[2] Istanbul Medicana Atasehir Hosp, Dept Pulm Med, Istanbul, Turkey
[3] Koc Univ, Sch Med, Div Nephrol, Dept Med, Istanbul, Turkey
来源：
CLINICAL KIDNEY JOURNAL | 2022年 / 15卷 / 05期
关键词：
chronic kidney disease; COVID-19; hypertension; renin angiotensin system;
D O I：
10.1093/ckj/sfac001
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Patients with chronic kidney disease, chronic heart failure and hypertension have an increased risk of coronavirus disease 2019 (COVID-19)-related death. Renin-angiotensin-aldosterone system (RAS) blockers are commonly prescribed to decrease morbidity and mortality in these conditions. Following the pre-clinical demonstration of COVID-19 viral entry into cells via angiotensin-converting enzyme-2, the use of RAS blockers was questioned in infected individuals. Theodorakopoulou et al. extensively review the pathophysiology behind that hypothesis and observational or clinical trials on RAS blockers and COVID-19. Despite being a scientific hot spot of an ongoing debate, discontinuation of RAS blockers is not associated with improved clinical outcomes in COVID-19 and may have potential harmful effects, including exacerbation of the underlying disease.
引用
收藏
页码：852 / 854
页数：3
相关论文
共 11 条
  • [1] A brand-new cardiorenal syndrome in the COVID-19 setting
    Apetrii, Mugurel
    Enache, Stefana
    Siriopol, Dimitrie
    Burlacu, Alexandru
    Kanbay, Asiye
    Kanbay, Mehmet
    Scripcariu, Dragos
    Covic, Adrian
    [J]. CLINICAL KIDNEY JOURNAL, 2020, 13 (03) : 291 - 296
  • [2] Kidney disease and electrolytes in COVID-19: more than meets the eye
    Carriazo, Sol
    Kanbay, Mehmet
    Ortiz, Alberto
    [J]. CLINICAL KIDNEY JOURNAL, 2020, 13 (03) : 274 - 280
  • [3] Pathological features of COVID-19 infection from biopsy and autopsy series
    Copur, Sidar
    Kanbay, Asiye
    Afsar, Baris
    Elsurer Afsar, Rengin
    Kanbay, Mehmet
    [J]. TUBERKULOZ VE TORAKS-TUBERCULOSIS AND THORAX, 2020, 68 (02): : 160 - 167
  • [4] COVID-19 and acute kidney injury
    Ertuglu, Lale A.
    Kanbay, Asiye
    Afsar, Baris
    Elsurer Afsar, Rengin
    Kanbay, Mehmet
    [J]. TUBERKULOZ VE TORAKS-TUBERCULOSIS AND THORAX, 2020, 68 (04): : 407 - 418
  • [5] Kanbay M., 2021, INT UROL NEPHROL
  • [6] COVID-19 and hypertension-evidence and practical management: Guidance from the HOPE Asia Network
    Kario, Kazuomi
    Morisawa, Yuji
    Sukonthasarn, Apichard
    Turana, Yuda
    Chia, Yook-Chin
    Park, Sungha
    Wang, Tzung-Dau
    Chen, Chen-Huan
    Tay, Jam Chin
    Li, Yan
    Wang, Ji-Guang
    [J]. JOURNAL OF CLINICAL HYPERTENSION, 2020, 22 (07) : 1109 - 1119
  • [7] Risk Factors Associated With In-Hospital Mortality in a US National Sample of Patients With COVID-19
    Rosenthal, Ning
    Cao, Zhun
    Gundrum, Jake
    Sianis, Jim
    Safo, Stella
    [J]. JAMA NETWORK OPEN, 2020, 3 (12)
  • [8] Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients
    Rossi, Gian Paolo
    Sanga, Viola
    Barton, Matthias
    [J]. ELIFE, 2020, 9
  • [9] Renin-angiotensin system blockers during the COVID-19 pandemic: an update for patients with hypertension and chronic kidney disease
    Theodorakopoulou, Marieta P.
    Alexandrou, Maria-Eleni
    Boutou, Afroditi K.
    Ferro, Charles J.
    Ortiz, Alberto
    Sarafidis, Pantelis
    [J]. CLINICAL KIDNEY JOURNAL, 2022, 15 (03) : 397 - 406
  • [10] Short-term effects of withdrawing angiotensin converting enzyme inhibitor therapy on home self-measured blood pressure in hypertensive patients
    Vaur, L
    Bobrie, G
    Dutrey-Dupagne, C
    Dubroca, I
    Vaisse, B
    d'Yvoire, MB
    Elkik, F
    Chatellier, G
    Menard, J
    [J]. AMERICAN JOURNAL OF HYPERTENSION, 1998, 11 (02) : 165 - 173
12